Neutralizing antibodies against SARS-CoV-2 can activate IL-18 and IL-16, myeloid chemotaxis, and activation of lymphocytes, monocytes, and natural killers, which lead to neutrophil activation, hypercoagulation, and thrombosis (38). The gene discussed is IL18; the disease is thrombophilia.